Evidence map›Paper›PMID 31413601›Full record

ArticleInfection and drug resistance2019

Characterization of NDM-5- and CTX-M-55-coproducing

Tsuyoshi Sekizuka, Yuba Inamine, Takaya Segawa, Makoto Kuroda

Abstract read
In one paragraph

Article in Infection and drug resistance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Cross-species transmission ofFrontiers in cellular and infection microbiology · 2026
    Review
  3. Article
  4. First Report in the Americas ofAntibiotics (Basel, Switzerland) · 2025
    Article
  5. Infection and drug resistance · 2025
    Article
  6. Article
  7. NDM-5-carrying3 Biotech · 2023
    Article
  8. Article
  9. Article
  10. Prevalence of Chromosomally LocatedMicrobiology spectrum · 2022
    Article
  11. Review
  12. Article
  13. Molecular characterization ofVeterinary world · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Emergence of NDM-5 Producing Carbapenem-ResistantFrontiers in public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tsuyoshi SekizukaLaboratory of Bacterial Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Yuba InamineLaboratory of Bacterial Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Takaya SegawaLaboratory of Bacterial Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
Makoto KurodaLaboratory of Bacterial Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNew Delhi metallo-β-lactamase (NDM)-5-producing Enterobacteriaceae have been detected in rivers, sewage, and effluents from wastewater treatment plants (WWTPs). Environmental contamination due to discharged effluents is of particular concern as NDM variants may be released into waterways, thereby posing a risk to humans. In this study, we collected effluent samples from a WWTP discharged into a canal in Tokyo Bay, Japan.

methodsTesting included the complete genome sequencing of

resultsThe complete genome sequencing of GSH8M-2 revealed that it was an NDM-5-producing

conclusionThis is the first report of environmental NDM-5-producing

Indexed as

carbapenemaseCTX-M-55IncX1IncX3NDM-5sewage

Identifiers

PMID31413601
PMCPMC6662510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.